Rigid bronchoscopy represents a challenge for anesthesiologists because it requires allowing the interventionist easy access to the airway with an adequate degree of muscle paralysis while maintaining proper ventilation and oxygenation (
2-
4). For any anesthetic procedure, the combination of hypnosis, analgesia, muscular relaxation, and Total Intravenous Anesthesia (TIVA) is required. Specific considerations for airway surgery via rigid bronchoscopy include the need for a rapid and complete offset of anesthetic agents.
Until the development of propofol, TIVA was rarely performed for surgeries with planned extubation owing to the prolonged emergences. Infusing propofol using pharmacokinetic parameters to target blood concentrations has been considered a significant improvement in propofol administration. Propofol has several advantages over other anesthetics, one of which is a more relaxing effect on the pharyngeal musculature compared to thiopental (
5), a commonly used anesthetic induction agent. In particular, the intravenous agent is more useful than the inhalation gas due to a large amount of leakage around the scope without packing.
In the past, surgery was the primary method of treatment for central airway obstruction. Recently, palliative procedures have been widely used, such as laser resection, coagulation, balloons, and insertion of silicone stents using rigid bronchoscopes (
6-
8). However, even if the airway is expected to be permanently secured using the stent, some complications may arise (
9). Complication rates vary depending on the patient health status and the performed procedure (
10-
12). Ost et al described that the predictors of the increased complication rate of therapeutic bronchoscopy include emergent situation, ASA score, repetition, and the need for moderate sedation (
13). In our study, all patients underwent rigid bronchoscopy under general anesthesia, and there were no systemic cardiovascular complications that could occur during hypoxemia and hypercapnia. However, there were some local complications. Hemorrhage was the most frequent adverse event, occurring in 7% of patients, but no additional procedure was required for hemostasis. One patient developed pneumothorax, and chest tube insertion was performed.
Endobronchial tumor destruction and removal are commonly performed using rigid bronchoscopy. Other frequently used indications include mechanical dilation, endobronchial ablation, and airway stent placement for obstructions, tracheoesophageal fistulae, or tracheobronchomalacia (
14-
16). In this study, the most frequent indication for this procedure was a therapeutic approach to mass effects, such as granulations and tumor growth (46.9%).
This study has some limitations. The number of patients was small, and the patient’s actual plasma drug levels were not confirmed. In addition, due to the retrospective nature of the study, various aspects were not considered because the results were interpreted based only on the recorded objective facts.
Nevertheless, we found that the dose of administered propofol decreased over time. This pattern was specific to propofol but not to remifentanil during TIVA. However, the dose administered per minute was not significantly correlated with the number of times the procedure was repeated in the same patient. These results are associated with the pharmacokinetic properties of both drugs, and understanding these mechanisms will help in the adequate administration of the drug. Therefore, when maintaining anesthesia with TIVA using propofol in a rigid bronchoscope procedure, caution should be exercised since large drug doses may be required from the early stage.